Premium
Milacemide: A Placebo‐Controlled Study in Senile Dementia of the Alzheimer Type
Author(s) -
Dysken Maurice W.,
Mendels Joseph,
LeWitt Peter,
Reisberg Barry,
Pomara Nunzio,
Wood James,
Skare Stacy,
Fakouhi J. Daniel,
Herting Robert L.
Publication year - 1992
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1111/j.1532-5415.1992.tb02019.x
Subject(s) - medicine , placebo , alzheimer's disease , dementia , randomized controlled trial , psychiatry , disease , pathology , alternative medicine
Objective Milacemide, a MAO‐B inhibitor that is also a prodrug for glycine, was tested as a treatment for senile dementia of the Alzheimer type (SDAT) because of its potential for enhancing cognition in animal models of impaired learning and memory. Design Double‐blind, placebo‐controlled, randomized clinical trial. Setting Sixteen study sites, both university‐affiliated and private. Patients A total of 228 outpatients (116 men and 112 women) with SDAT, ranging in age from 49–93 years. Intervention: 1200 mg/day milacemide treatment for 1 month (113 patients received milacemide, and 115 patients received placebo). Main Outcome Measures Alzheimer's Disease Assessment Scale and the Mini‐Mental State Examination. Results Milacemide‐treated SDAT patients did not show significant improvement in any of the outcome measures used. Significant elevations in liver enzymes in four subjects were of sufficient magnitude to necessitate withdrawal from the study. Conclusions Milacemide does not appear to be an effective treatment in enhanci g cognition in SDAT patients.